含维奈克拉方案治疗新诊断不适合强烈化疗急性髓系白血病的专家建议(2024年版)  

Expert recommendations on venetoclax-based regimens for treatment of newly diagnosed unfit acute myeloid leukemia(2024 version)

作　　者：中国临床肿瘤学会(CSCO)白血病专家委员会 马军[2] 陈苏宁[3] 贡铁军[2] 魏辉[4] 张钰[5] Leukemia Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology and Oncology,Harbin 150010)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010 [3]苏州大学附属第一医院 [4]中国医学科学院、北京协和医学院血液学研究所、血液病医院 [5]南方医科大学南方医院

出　　处：《白血病．淋巴瘤》2024年第11期641-648,共8页Journal of Leukemia & Lymphoma

摘　　要：维奈克拉是治疗急性髓系白血病(AML)的新型bcl-2靶向药物,国内外临床指南推荐维奈克拉联合阿扎胞苷为新诊断不适合强烈化疗(Unfit)AML患者的标准治疗,目前该方案药物已被纳入我国国家基本医疗保险药品目录。全国25位白血病领域专家组成工作组,采用德尔菲法达成共识,制定了涵盖9个临床问题和25条专家共识原则的指导意见,这些意见涵盖临床重点、关键问题,为中国医生规范和安全应用含维奈克拉方案治疗新诊断Unifit AML提供指导。Venetoclax is a novel bcl-2 targeted drug for the treatment of acute myeloid leukemia(AML).Clinical guidelines at home and abroad recommend the regimen of venetoclax combined with azacitidine as the standard of care for the newly diagnosed AML patients which are unfit for intensive chemotherapy.The drugs in this regimen are currently included in the China's national reimbursement drug list.A working group consisting of 25 Chinese leukemia experts reached a consensus using the Delphi method and developed guidance covering 9 clinical issues and 25 expert recommendations.These recommendations included the key clinical issues and provided practical guidance for Chinese doctors to standardize the usage of venetoclax-based regimens for treatment of newly diagnosed unfit AML.

关 键 词：白血病 髓样 急性 维奈克拉 药物疗法 联合 

分 类 号：R733.71[医药卫生—肿瘤]